Multiple Sclerosis Clinical Trials in San Francisco, CA

24 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers	Phase 1/2	Ashvattha Therapeutics, Inc.	<1 mi
Study of COYA 302 for the Treatment of ALS	Phase 2	Coya Therapeutics	<1 mi
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis	Phase 4	Novartis Pharmaceuticals	<1 mi
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)	—	University of California, San Francisco	<1 mi
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis	Phase 4	University of California, San Francisco	<1 mi
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS	—	University of California, San Francisco	<1 mi
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy	Phase 1/2	University of California, San Francisco	<1 mi
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk	—	TG Therapeutics, Inc.	<1 mi
Care in Multiple Sclerosis (MS)	—	NYU Langone Health	<1 mi
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis	Phase 2	Emmanuelle Waubant, MD PhD	<1 mi
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Phase 2	University of California, San Francisco	<1 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis	Phase 2	Novartis Pharmaceuticals	<1 mi
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS	Phase 2	PhenoNet, Inc.	<1 mi
ECoG BMI for Motor and Speech Control	N/A	Karunesh Ganguly	<1 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	8 mi
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis	Phase 3	Sanofi	10 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	28 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	28 mi
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis	Phase 1	Stanford University	28 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	28 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	28 mi
A Study of AZD0120 in Autoimmune Diseases	Phase 1	AstraZeneca	28 mi
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis	Phase 1	Hoffmann-La Roche	28 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	49 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.